Zhao M M, Hwa J, Perez D M
Department of Molecular Cardiology, Cleveland Clinic Research Institute, Ohio 44195, USA.
Mol Pharmacol. 1996 Nov;50(5):1118-26.
alpha 1-Adrenergic receptor (AR) subtypes mediate many effects of the sympathetic nervous system. Although structurally similar, the three cloned subtypes (alpha 1a-AR, alpha 1b-AR, and alpha 1d-AR) bind a series of ligands with different relative potencies. This is particularly true for the alpha 1a-AR, which recognizes a number of ligands with 10-100-fold higher affinity than the alpha 1b or alpha 1d subtypes. Because ligands are hypothesized to bind to receptor residues that are located in the transmembrane (TM) spanning domains, subtype differences in ligand recognition are likely the result of differences in the binding properties of nonconserved TM residues. We previously reported on the identification of two TM residues in the alpha 1b-AR that converted the agonist binding profile entirely to that of the alpha 1a-AR when mutated to corresponding alpha 1a-AR residues. We now report on the determinants of antagonist selectivity between these two alpha 1-AR subtypes. Construction of a chimera in which the entire fifth TM and a portion of the putative second extracellular loop of the hamster alpha 1b-AR was replaced with the corresponding region of the rat alpha 1a-AR revealed that the chimera accounted for all of the higher binding affinity (8-29-fold) seen in the alpha 1a-AR for two antagonists, phentolamine and WB4101. Using site-directed mutagenesis, we further analyzed individual point mutations making up this chimera. We found that three adjacent residues, which were located on the extracellular loop of the fifth TM, are fully responsible for this higher antagonist binding affinity in the alpha 1a-AR. These three point mutations (G196Q, V1971, T198N) in the alpha 1b-AR were additive and sufficient in their effects on changing antagonist-binding profiles to that of the alpha 1a-AR. Reversal of these three residues in the alpha 1a-AR to their corresponding residues in the alpha 1b-AR completely reversed the antagonist affinity to wild-type alpha 1b-AR values. To aid in molecular modeling, the use of organic chemicals that mimic key structures of the antagonists were used in competitive ligand-binding studies with the mutated receptors. These results indicated the orientation of both phentolamine and WB4101 in the alpha 1-AR binding pocket. Together, the data indicate that alpha 1-antagonists may bind near the surface of the receptor, much like the peptide hormone receptors, and not deep within the TM regions, where the ligand-binding pocket was first proposed and identified for alpha 1 agonists.
α1 - 肾上腺素能受体(AR)亚型介导交感神经系统的多种效应。尽管在结构上相似,但三种克隆的亚型(α1a - AR、α1b - AR和α1d - AR)与一系列配体结合的相对亲和力不同。对于α1a - AR来说尤其如此,它识别许多配体的亲和力比α1b或α1d亚型高10 - 100倍。由于推测配体与位于跨膜(TM)结构域中的受体残基结合,配体识别的亚型差异可能是由于非保守TM残基结合特性的差异所致。我们之前报道了在α1b - AR中鉴定出两个TM残基,当它们突变为相应的α1a - AR残基时,激动剂结合谱完全转变为α1a - AR的谱。我们现在报道这两种α1 - AR亚型之间拮抗剂选择性的决定因素。构建一个嵌合体,其中仓鼠α1b - AR的整个第五TM和假定的第二个细胞外环的一部分被大鼠α1a - AR的相应区域取代,结果显示该嵌合体对两种拮抗剂酚妥拉明和WB4101表现出α1a - AR中所见的所有更高的结合亲和力(8 - 29倍)。使用定点诱变,我们进一步分析了构成该嵌合体的单个点突变。我们发现位于第五TM细胞外环上的三个相邻残基完全负责α1a - AR中这种更高的拮抗剂结合亲和力。α1b - AR中的这三个点突变(G196Q、V197I、T198N)在改变拮抗剂结合谱至α1a - AR的谱方面具有累加效应且足够有效。将α1a - AR中的这三个残基逆转为α1b - AR中的相应残基,完全将拮抗剂亲和力逆转至野生型α1b - AR值。为了辅助分子建模,在与突变受体的竞争性配体结合研究中使用了模拟拮抗剂关键结构的有机化学物质。这些结果表明了酚妥拉明和WB4101在α1 - AR结合口袋中的取向。总之,数据表明α1 - 拮抗剂可能在受体表面附近结合,很像肽激素受体,而不是在最初为α1激动剂提出并确定配体结合口袋的TM区域深处。